Loading
institutionsInstitution
Antwerp University Hospital (UZA)
Belgium's Antwerp university hospital, where Jan Vermorken led EXTREME, the trial that made cetuximab plus chemotherapy the first-line standard for recurrent head and neck cancer for a decade.
Also called: UZAUniversitair Ziekenhuis Antwerpen
Overview
Antwerp University Hospital (UZA) is the academic hospital of the University of Antwerp, at Edegem south of the city. Its Department of Medical Oncology, under Jan Vermorken, coordinated the EXTREME trial, reported in the New England Journal of Medicine in 2008, in which adding cetuximab to platinum and fluorouracil lengthened survival in recurrent or metastatic head and neck squamous-cell carcinoma. The department has long been active in EORTC gynaecological and head and neck trials.
Location
Edegem, BE
Type
hospital · Universiteit Antwerpen
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#659 · 2 points (0 Newsweek + 0 NCI + 2 from 1 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.
Matched to Antwerp University Hospital, including child institutions. 330 works · 4,583 citations · 73% open access · 17% clinical trials · 1% reviews.
Oncology works per year
702022
792023
722024
592025
502026
Most works
- Hans Prenen48 works
- Marc Peeters41 works
- Geert Roeyen29 works
- Sébastien Anguille28 works
- Evelien Smits16 works
- Wiebren A.A. Tjalma15 works
- Tim Van den Wyngaert15 works
- Karen Paula Geboes14 works
- Filip Lardon13 works
- Ivan Borbath12 works
Most cited
- Head and neck cancer
- Gynaecological cancer
- EORTC trials
Similar pages
- TrialEXTREME
Shares Jan B. Vermorken, Head and neck squamous cell carcinoma.